secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001753926-26-000097
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pelthos secures up to $50M senior secured term loan from Horizon; $30M drawn at close
--------------------------------------------------------------------------------

- Up to $50M senior secured term loan facility from Horizon Technology Finance; $30M funded at closing on Jan 12, 2026.
- Remaining $20M available upon achieving milestones; interest rate prime +3.75% (currently 10.50%) with 6.75% floor.
- Proceeds to commercialize ZELSUVMI, launch Xepi and Xeglyze, and for working capital.
- Issued warrants for 65,488 shares at $27.49 per share to Horizon; loan matures Jan 31, 2031.
- As of Sept 30, 2025, cash and investments $14.2M; augmented by $18M convertible notes in Nov 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392626000097/0001753926-26-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392626000097/g085079_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-26-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer